Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.95B 4.32B 3.99B 3.68B 6.93B 477B 7.09B 47.7B 18.76B 233B 18.59B 18.18B 804B P/E 2026 *
12.8x
P/E 2027 * 11.2x
Enterprise Value 5B 4.37B 4.03B 3.72B 7.01B 482B 7.17B 48.23B 18.97B 236B 18.79B 18.38B 812B EV / Sales 2026 *
3.98x
EV / Sales 2027 * 3.48x
Free-Float
97.23%
Yield 2026 *
-
Yield 2027 * -
Current month-0.56%
1 month+7.23%
1 week 35.2
Extreme 35.2
35.8
1 month 33.4
Extreme 33.4
36
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.11% - - 4.95B
+0.85%-3.11%+49.29%+162.34% 1,043B
+1.23%-2.34%+53.56%+58.28% 602B
+0.04%+1.83%+33.53%+87.11% 449B
+0.78%-0.39%+30.44%+23.23% 327B
+1.41%+0.56%+31.41%+47.13% 279B
-0.27%-5.69%+20.68%+21.99% 264B
-1.42%+0.73%+22.50%+61.06% 201B
-1.48%-0.42%+22.24%+73.96% 169B
-0.36%+3.30%+1.79%-31.03% 143B
Average +0.04%-0.68%+29.49%+56.01% 386.34B
Weighted average by Cap. +0.37%-1.82%+37.79%+83.50%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.01B 935M 1.76B 121B 1.8B 12.12B 4.77B 59.33B 4.72B 4.62B 204B 1.31B 1.14B 1.05B 972M 1.83B 126B 1.87B 12.61B 4.96B 61.68B 4.91B 4.8B 212B
Net income 414M 362M 334M 308M 581M 39.91B 594M 3.99B 1.57B 19.55B 1.56B 1.52B 67.29B 473M 413M 381M 351M 662M 45.54B 677M 4.56B 1.79B 22.3B 1.78B 1.74B 76.78B
Net Debt 54.5M 47.63M 43.95M 40.51M 76.35M 5.25B 78.05M 525M 207M 2.57B 205M 200M 8.85B -403M -353M -325M -300M -565M -38.85B -578M -3.89B -1.53B -19.03B -1.51B -1.48B -65.5B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Date Price Change
17/07/26 35.60 0.00%
16/07/26 €35.60 -0.56%
15/07/26 €35.80 +1.13%
14/07/26 €35.40 +0.57%
13/07/26 €35.20 -1.12%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
40.59USD
Average target price
50.83USD
Spread / Average Target
+25.24%

Quarterly revenue - Rate of surprise